The report details the administration’s potential plans for a variety of issues that will directly impact pharma.

Pfizer's inclacumab fails Phase III study for sickle cell disease, disappointing the community while the company remains ...

Strategies for biopharma in integrating agentic AI—to achieve incremental gains in efficiency, while delivering meaningful ...

Superluminal partners with Eli Lilly to develop AI-driven small molecule therapies targeting GPCRs for obesity and ...

The FDA has granted full approval to Precigen’s Papzimeos (zopapogene imadenovec-drba) for adults with recurrent respiratory papillomatosis (RRP). Papzimeos is a non-replicating adenoviral ...

The milestone payment is partially funded through Sarepta’s Arrowhead stock sale as both companies push forward with ...

Pharmaceutical Executive delivers strategic insights for pharma leaders, covering commercialization, market access, R&D, and leadership to drive success.

VP, late development, immunology at The Janssen Pharmaceutical Companies of Johnson & Johnson.

Seal Rock Therapeutics joins The Michael J. Fox Foundation's LITE program to help advance research and developments in ...

Oikos Fusion offers a nutrient-dense dairy drink designed to support muscle mass and digestive health during weight loss ...

The statement appears to be a response to the President’s recent publication of letters to 17 pharma companies about reducing ...

Eli Lilly is increasing Mounjaro's UK price by 170% to match European market levels, with the highest dose now costing £330.